Why the study?
Does edoxaban prevent recurrent symptomatic venous thromboembolism in patients with acute venous thromboembolism compared to warfarin?
Population
8,240 patients with acute symptomatic venous thromboembolism who had initially received heparin.
Comparison
Edoxaban 60 mg once daily for 3 to 12 months… vs Warfarin for 3 to 12 months, administered after…
Design
RCT, randomly assigned, double-blind
Follow-up
3 to 12 months
Loading...
Supports edoxaban as a convenient option for acute VTE; extends the NOAC evidence base beyond prior warfarin comparisons.
Does edoxaban prevent recurrent symptomatic venous thromboembolism in patients with acute venous thromboembolism compared to warfarin?
Edoxaban is an effective and safer alternative to warfarin for the treatment of acute venous thromboembolism, demonstrating noninferior efficacy and superior safety regarding bleeding.
A 2013 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: